MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

Начало・Списък с акции・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

1.63 1.87

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.55

Максимум

1.63

Ключови измерители
By Trading Economics
Приходи	-2.8M -16M
Продажби	-8.7M 5.5M
Марж на печалбата	-282.723
Служители	81
EBITDA	-4.2M -15M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+140.88% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-12M 640M
Предишно отваряне	-0.24
Предишно затваряне	1.63

Настроения в новините

By Acuity

94%

3 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

0.6863 / 0.72 Подкрепа & съпротива

Lexicon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.04.2026 г., 23:17 ч. UTC

Печалби

Samsung Forecasts Record First-Quarter Operating Profit

6.04.2026 г., 23:00 ч. UTC

Горещи акции

Stocks to Watch: Health Insurers, Mawson, Owlet

6.04.2026 г., 22:13 ч. UTC

Значими двигатели на пазара

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6.04.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6.04.2026 г., 17:09 ч. UTC

Значими двигатели на пазара

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6.04.2026 г., 16:56 ч. UTC

Значими събития в новините

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6.04.2026 г., 14:47 ч. UTC

Значими двигатели на пазара

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6.04.2026 г., 23:58 ч. UTC

Пазарно говорене

Значими събития в новините

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6.04.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6.04.2026 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6.04.2026 г., 23:15 ч. UTC

Пазарно говорене

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6.04.2026 г., 22:52 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

6.04.2026 г., 22:52 ч. UTC

Пазарно говорене

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6.04.2026 г., 22:14 ч. UTC

Пазарно говорене

Correction to Live Cattle Futures Article

6.04.2026 г., 20:56 ч. UTC

Пазарно говорене

Mexican Private Consumption Fell in January -- Market Talk

6.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

6.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.04.2026 г., 19:58 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.04.2026 г., 19:58 ч. UTC

Пазарно говорене

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6.04.2026 г., 19:11 ч. UTC

Пазарно говорене

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6.04.2026 г., 19:06 ч. UTC

Пазарно говорене

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6.04.2026 г., 19:03 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

6.04.2026 г., 19:03 ч. UTC

Пазарно говорене

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6.04.2026 г., 18:36 ч. UTC

Придобивния, сливания и поглъщания

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6.04.2026 г., 17:59 ч. UTC

Пазарно говорене

Значими събития в новините

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6.04.2026 г., 17:13 ч. UTC

Придобивния, сливания и поглъщания

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6.04.2026 г., 16:33 ч. UTC

Пазарно говорене

Oil Futures Steady as Market Awaits Trump -- Market Talk

6.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.04.2026 г., 14:59 ч. UTC

Печалби

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Lexicon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

140.88% нагоре

12-месечна прогноза

Среден 3.83 USD 140.88%

Висок 6 USD

Нисък 1 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Lexicon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Lexicon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.6863 / 0.72Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Настроение

By Acuity

3 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.